Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

By sjmartinez • March 4, 2023

Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Feb 28:S0140-6736(23)00350-1. doi: 10.1016/S0140-6736(23)00350-1. Epub ahead of print. PMID: 36868261.

Tags: Allergy & Immunology, Publications

Psychosocial issues and quality of life associated with food allergy

Kachru R. Psychosocial issues and quality of life associated with food allergy. J Food Allergy. 2024 Jul 8;2(1):95-98. doi: 10.2500/jfa.2020.2.200025. PMID: 39022158; PMCID: PMC11250222.

Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma

Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Dupilumab[...]

The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy

Olivieri B, Günaydın FE, Corren J, Senna G, Durham SR. The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy. Ann Allergy[...]